Table 2. Evolution of first line treatment for recurrent/metastatic cervical cancer.

	First line therapy
	GOG-204	GOG-240	Keynote-826
Treatment	CDDP+Paclitaxel	Doublet+Bevacizumab	ChemoRx+Pembrolizumab with or without Bevacizumab
Median OS	12.0 mo	17.0 mo, HR 0.71	24.4 mo, HR 0.64
ORR	29.1%	48.0%	68.1% in PD-L1+≥1%
Citaion	Monk BJ, et al. J Clin Oncol 2009;27:4649-55.	Tewari KS, et al. N Engl J Med 2014;370:734-43.	Colombo N, et al. N Engl J Med 2021;385:1856-67.

HR, hazard ratio; ORR, overall response rate; OS, overall survival; PD-L1, programmed death-ligand 1.